IL-10 in Mycobacterial Infection

  • Peter A. Sieling
  • Robert L. Modlin
Part of the Molecular Biology Intelligence Unit book series (MBIU)


Infection by Mycobacterium leprae elicits a spectrum of clinical presentations.1 Because these clinical manifestations correlated with the level of cell-mediated immunity (CMI) to the pathogen, leprosy serves as a useful model to study human immune responses to infection. At one pole, tuberculoid patients are able to restrict growth of the pathogen as demonstrated by the presence of relatively few skin lesions containing few bacilli. These patients have strong CMI to the pathogen as evidenced by vigorous T-cell responses in vitro and skin test reactivity to challenge with M. leprae. At the opposite pole, lepromatous patients have disseminated disease as manifested by numerous skin lesions containing large numbers of bacilli. The T cells of these patients are specifically unresponsive to M. leprae although they produce significant quantities of antibodies against M. leprae antigens.


Pleural Fluid Cutaneous Leishmaniasis Mycobacterial Infection Lepromatous Leprosy Skin Test Reactivity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ridley DS, Jopling WH. Classification of leprosy according to immunity A five-group system. Int J Lepr 1966; 34: 255–273.Google Scholar
  2. 2.
    Roper WH, Waring JJ. Primary serofibrinous pleural effusion in military personnel. Amer Rev Tuberc 1955; 71: 616–634.Google Scholar
  3. 3.
    Yamamura M, Uyemura K, Deans RJ et al. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277–279.PubMedCrossRefGoogle Scholar
  4. 4.
    Salgame P, Abrams JS, Clayberger C et al. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T-cell clones. Science 1991; 254: 279–282.PubMedCrossRefGoogle Scholar
  5. 5.
    Yamamura M, Wang X-H, Ohmen JD et al. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992; 149: 1470–1475.PubMedGoogle Scholar
  6. 6.
    Barnes PF, Lu S, Abrams JS, et al. Cytokine production at the site of disease of human tuberculosis. Infect Immun 1993; 61: 3482–3489.PubMedGoogle Scholar
  7. 7.
    Fiorentino DF, Bond MW, Mosmann TR. Two types of mouse T-helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th 1 clones. J Exp Med 1989; 170: 2081–2095.PubMedCrossRefGoogle Scholar
  8. 8.
    Sieling PA, Abrams JS, Yamamura M et al. Immunosuppressive roles for interleukin-10 and interleukin-4 in human infection: In vitro modulation of T cell responses in leprosy. J Immunol 1993; 150: 5501–5510.PubMedGoogle Scholar
  9. 9.
    Mutis T, Kraakman EM, Cornelisse YE et al. Analysis of cytokine production by Mycobacterium-reactive T cells. Failure to explain Mycobacterium leprae-specific nonresponsiveness of peripheral blood T cells from lepromatous leprosy patients. J Immunol 1993; 150: 4641–4651.PubMedGoogle Scholar
  10. 10.
    de Waal Malefyt R, Abrams J, Bennett B et al. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An auto-regulatory role of IL-10 produced by monocytes. J Exp Med 1991; 174: 1209–1220.PubMedCrossRefGoogle Scholar
  11. 11.
    Moreno C, Mehlert A, Lamb J. The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell proliferation. Clin Exp Immunol 1988; 74: 206–210.PubMedGoogle Scholar
  12. 12.
    Sibley LD, Hunter SW, Brennan PJ et al. Mycobacterial lipoarabinomannan inhibits gamma interferon-mediated activation of macrophages. Infect Immun 1988; 56: 1232–1236.PubMedGoogle Scholar
  13. 13.
    Barnes PF, Chatterjee D, Abrams JS et al. Cytokine production induced by Mycobacterium tuberculosis lipoarabinomannan. Relationship to chemical structure. J Immunol 1992; 149: 541–547.PubMedGoogle Scholar
  14. 14.
    Rook GAW, Steele J, Fraher L et al. Vitamin D3, gamma interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 1986; 57: 159–163.PubMedGoogle Scholar
  15. 15.
    Nathan CF, Kaplan G, Levis WR et al. Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 1986; 315: 6–15.PubMedCrossRefGoogle Scholar
  16. 16.
    Dustin ML, Singer KH, Tuck DT et al. Adhesion of T lymphoblasts to epidermal keratinocytes is regulated by interferon-gamma and is mediated by intercellular adhesion molecule 1 (ICAM-1). J Exp Med 1988; 167: 1323–1340.PubMedCrossRefGoogle Scholar
  17. 17.
    Gately MK, Desai BB, Wolitsky AG et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874–882.PubMedGoogle Scholar
  18. 18.
    Hsieh C, Macatonia SE, Tripp CS et al. Development of Thl CD4’ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547–549.PubMedCrossRefGoogle Scholar
  19. 19.
    Heinzel FP, Schoenhaut DS, Rerko RM et al. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993; 177: 1505–1509.PubMedCrossRefGoogle Scholar
  20. 20.
    Sypek JP, Chung CL, Mayor SEH et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 response. J Exp Med 1993; 177: 1797–1802.PubMedCrossRefGoogle Scholar
  21. 21.
    Seder RA, Gazzinelli R, Sher A et al. Interleukin 12 acts directly on CD4’ T cells to enhance priming for interferon-gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci USA 1993; 90: 10188–10192.PubMedCrossRefGoogle Scholar
  22. 22.
    D’Andrea A, Rengaraju M, Valiante NM et al. Production of natural killer cell stimulatory cell factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med 1992; 176: 1387–1398.PubMedCrossRefGoogle Scholar
  23. 23.
    Stern AS, Podlaski FJ, Hulmes JD et al. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990; 87: 6808–6812.PubMedCrossRefGoogle Scholar
  24. 24.
    Sieling PA, Wang X-H, Gately MK et al. IL-12 regulates T helper Type 1 cytokine responses in human infectious disease. 1993, J Immunol. in press..Google Scholar
  25. 25.
    D’Andrea A, Aste-Amezaga M, Valiante NM et al. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J Exp Med 1993; 178: 1041–1048.PubMedCrossRefGoogle Scholar
  26. 26.
    Groh V, Fabbi M, Hochstenbach F et al. Double-negative (CD4–CD8-) lymphocytes bearing T-cell receptor alpha and beta chains in normal human skin. Proc Natl Acad Sci USA 1989; 86: 5059–5063.PubMedCrossRefGoogle Scholar
  27. 27.
    Lanier LL, Weiss A. Presence of Ti (WT31) negative T lymphocytes in normal blood and thymus. Nature 1989; 324: 268–270.CrossRefGoogle Scholar
  28. 28.
    Shivakumar S, Tsokos GC, Datta SK. T-cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4’ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol 1989; 143: 103–112.PubMedGoogle Scholar
  29. 29.
    Brooks EG, Wirt DP, Goldblum RM et al. Double negative (CD4- CD8-) T cells with an oc/J3 T cell receptor. Non-MHC-restricted cytolytic activity and lymphokine production. J Immunol 1990; 144: 4507–4512.PubMedGoogle Scholar
  30. 30.
    Porcelli S, Morita CT, Brenner MB. CD1b restricts the response of human CD4–8- T lymphocytes to a microbial antigen. Nature 1992; 360: 593–597.PubMedCrossRefGoogle Scholar
  31. 31.
    Dellabona P, Casorati G, Friedli B et al. In vivo persistence of expanded clones specific for bacterial antigens within the human T cell receptor alpha/beta CD4–8- subset. J Exp Med 1993; 177: 1763–1771.PubMedCrossRefGoogle Scholar
  32. 32.
    Calabi F, Bradbury A. The CD1 system. Tissue Antigens 1991; 37: 1–9.CrossRefGoogle Scholar
  33. 33.
    Meunier L, Gonzalez-Ramos A, Cooper KD. Heterogeneous populations of class II MHC’ cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J Immunol 1993; 151: 4067–4080.PubMedGoogle Scholar
  34. 34.
    Kasinrerk W, Baumruker T, Majdic O et al. CD1 molecule expression on human monocytes induced by granulocyte-macrophage colony-stimulating factor. J Immunol 1993; 150: 579–584.PubMedGoogle Scholar
  35. 35.
    de Waal-Malefyt R, Haanen J, Spits H et al. Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibilty complex expression. J Exp Med 1991; 174: 915–924.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • Peter A. Sieling
  • Robert L. Modlin

There are no affiliations available

Personalised recommendations